Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5736-5746

  Blount, Kenneth F ^a,b,f   Megyola, Cynthia ^a   Plummer, Mark ^a   Osterman, David ^b,g   O'Connell, Tim ^b,h   Aristoff, Paul ^c   Quinn, Cheryl ^d   Chrusciel, R Alan ^e   Poel, Toni J ^e   Schostarez, Heinrich J ^e   Stewart, Catherine A ^e   Walker, Daniel P ^e   Wuts, Peter G M ^e   Breaker, Ronald R ^a  

^a YALE UNIVERSITY   (United States)

^b BioRelix Inc   (United States)

^c Aristoff Consulting LLC   (United States)

^d QnA Pharma Consulting LLC   (United States)

^e Kalexsyn Inc   (United States)

^f YALE CANCER CENTER   (United States)

^g ALEXION PHARMACEUTICALS   (United States)

^h NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 FLUOROPHENYL)BUTYL] 7,8 DIMETHYLPYRIDO[3,4 B]QUINOXALINE 1,3(2H,5H) DIONE; FIDAXOMICIN; FLAVINE MONONUCLEOTIDE; RIBOFLAVIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; RIBOSWITCH;

ACTINOMYCES; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTEROIDES; BIFIDOBACTERIUM; CECUM; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG BINDING; DRUG SYNTHESIS; FEMALE; HOMEOSTASIS; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PREVOTELLA; PRIORITY JOURNAL; RIBOSWITCH; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; ANTI-BACTERIAL AGENTS; CECUM; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FLAVIN MONONUCLEOTIDE; FLAVINS; MICE; MICE, INBRED C57BL; RIBOSWITCH;

EID: 84940924493     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01282-15     Document Type: Article

References (88)

1. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. http://dx.doi.org/10.1086/524891.
2. Silver LL. 2011. Challenges of antibacterial discovery. Clin Microbiol Rev 24:71-109. http://dx.doi.org/10.1128/CMR.00030-10.
3. Mandal M, Breaker RR 2004. Gene regulation by riboswitches. Nat Rev Mol Cell Biol 5:451-463. http://dx.doi.org/10.1038/nrm1403.
4. Serganov A. 2009. The long and the short of riboswitches. Curr Opin Struct Biol 19:251-259. http://dx.doi.org/10.1016/j.sbi.2009.02.002.
5. Roth A, Breaker RR 2009. The structural and functional diversity of metabolite-binding riboswitches. Annu Rev Biochem 78:305-334. http://dx.doi.org/10.1146/annurev.biochem.78.070507.135656.
6. Smith AM, Fuchs RT, Grundy FJ, Henkin TM 2010. Riboswitch RNAs: regulation of gene expression by direct monitoring of a physiological signal. RNA Biol 7:104-110. http://dx.doi.org/10.4161/rna.7.1.10757.
7. Breaker RR. 2011. Prospects for riboswitch discovery and analysis. Mol Cell 43:867-879. http://dx.doi.org/10.1016/j.molcel.2011.08.024.
8. Breaker RR. 2012. Riboswitches and the RNA world. Cold Spring Harb Perspect Biol 4(2):pii=a003566. http://dx.doi.org/10.1101/cshperspect.a003566.
9. Koedam JC. 1958. The mode of action of pyrithiamine as an inducer of thiamine deficiency. Biochim Biophys Acta 29:333-344. http://dx.doi.org/10.1016/0006-3002(58)90192-6.
10. Sudarsan N, Cohen-Chalamish S, Nakamura S, Emilsson GM, Breaker RR 2005. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem Biol 12:1325-1335. http://dx.doi.org/10.1016/j.chembiol.2005.10.007.
11. Sudarsan N, Wickiser JK, Nakamura S, Ebert MS, Breaker RR 2003. An mRNA structure in bacteria that controls gene expression by binding lysine. Genes Dev 17:2688-2697. http://dx.doi.org/10.1101/gad.1140003.
12. Lee ER, Blount KF, Breaker RR 2009. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol 6:187-194. http://dx.doi.org/10.4161/rna.6.2.7727.
13. Ott E, Stolz J, Lehmann M, Mack M. 2009. The RFN riboswitch of Bacillus subtilis is a target for the antibiotic roseoflavin produced by Streptomyces davawensis. RNA Biol 6:276-280. http://dx.doi.org/10.4161/rna.6.3.8342.
14. Blount KF, Wang XJ, Lim J, Sudarsan N, Breaker RR 2007. Antibacterial compounds that target lysine riboswitches. Nat Chem Biol 3:44-49. http://dx.doi.org/10.1038/nchembio842.
15. Kim JN, Blount KF, Puskarz I, Lim J, Link KH, Breaker RR 2009. Design and antimicrobial action of purine analogues that bind guanine riboswitches. ACS Chem Biol 4:915-927. http://dx.doi.org/10.1021/cb900146k.
16. Lünse CE, Schmidt MS, Wittmann V, Mayer G. 2011. Carba-sugars activate the glmS-riboswitch of Staphylococcus aureus. ACS Chem Biol 6:675-678. http://dx.doi.org/10.1021/cb200016d.
17. Blount KF, Breaker RR 2006. Riboswitches as antibacterial drug targets. Nat Biotechnol 24:1558-1564. http://dx.doi.org/10.1038/nbt1268.
18. Blount KF, Puskarz I, Penchovsky R, Breaker RR 2006. Development and application of a high-throughput assay for glmS riboswitch activators. RNA Biol 3:77-81. http://dx.doi.org/10.4161/rna.3.2.3102.
19. Deigan KE, Ferre-D'Amare AR. 2011. Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Acc Chem Res 44:1329-1338. http://dx.doi.org/10.1021/ar200039b.
20. Ster C, Allard M, Boulanger S, Lamontagne Boulet M, Mulhbacher J, Lafontaine DA, Marsault E, Lacasse P, Malouin F. 2013. Experimental treatment of Staphylococcus aureus bovine intramammary infection using a guanine riboswitch ligand analog. J Dairy Sci 96:1000-1008. http://dx.doi.org/10.3168/jds.2012-5890.
21. Gilbert SD, Reyes FE, Edwards AL, Batey RT 2009. Adaptive ligand binding by the purine riboswitch in the recognition of guanine and adenine analogs. Structure 17:857-868. http://dx.doi.org/10.1016/j.str.2009.04.009.
22. Mansjo M, Johansson J. 2011. The riboflavin analog roseoflavin targets an FMN-riboswitch and blocks Listeria monocytogenes growth, but also stimulates virulence gene-expression and infection. RNA Biol 8:674-680. http://dx.doi.org/10.4161/rna.8.4.15586.
23. Matsui K, Wang HC, Hirota T, Matsukawa H, Kasai S, Shinagawa K. 1982. Riboflavin production by roseoflavin-resistant strains of some bacteria. Agric Biol Chem 46:2003-2008. http://dx.doi.org/10.1271/bbb1961.46.2003.
24. Otani S, Takatsu M, Nakano M, Kasai S, Miura R. 1974. Roseoflavin, a new antimicrobial pigment from Streptomyces. J Antibiot (Tokyo) 27:86-87. (Letter.) http://dx.doi.org/10.7164/antibiotics.27.86.
25. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
26. Johnson S. 2009. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 33(Suppl 1):S33-S36. http://dx.doi.org/10.1016/S0924-8579(09)70014-7.
27. Johnson S. 2009. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58:403-410. http://dx.doi.org/10.1016/j.jinf.2009.03.010.
28. Kelly CP. 2012. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):21-27. http://dx.doi.org/10.1111/1469-0691.12046.
29. Krook A. 1981. Effect of metronidazole and sulfasalazine on the normal human faecal flora. Scand J Gastroenterol 16:587-592. http://dx.doi.org/10.3109/00365528109182016.
30. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE 1997. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 25:729-732. http://dx.doi.org/10.1086/513755.
31. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. 1996. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 173: 1129-1136. http://dx.doi.org/10.1093/infdis/173.5.1129.
32. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354-3359. http://dx.doi.org/10.1099/mic.0.042010-0.
33. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55:S132-S142. http://dx.doi.org/10.1093/cid/cis338.
34. Finegold SA, Molitoris D, Vaisanen ML, Song YL, Liu CX, Bolanos M. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 48:4898-4902. http://dx.doi.org/10.1128/AAC.48.12.4898-4902.2004.
35. Credito KL, Appelbaum PC 2004. Activity of OPT-80, a novel macrocycle, compared with thoseofeight other agents against selected anaerobic species. Antimicrob Agents Chemother 48:4430-4434. http://dx.doi.org/10.1128/AAC.48.11.4430-4434.2004.
36. Gerber M, Ackermann G. 2008. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Invest Drugs 17:547-553. http://dx.doi.org/10.1517/13543784.17.4.547.
37. Golan Y, Epstein L. 2012. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol 5:395-402. http://dx.doi.org/10.1177/1756283X12461294.
38. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
39. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613-1615. http://dx.doi.org/10.1128/AAC.05655-11.
40. Bakken JS. 2009. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15:285-289. http://dx.doi.org/10.1016/j.anaerobe.2009.09.007.
41. Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDIS Study Group. 2013. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother 68:1305-1311. http://dx.doi.org/10.1093/jac/dkt013.
42. Regulski EE, Breaker RR 2008. In-line probing analysis of riboswitches. Methods Mol Biol 419:53-67. http://dx.doi.org/10.1007/978-1-59745-033-1-4.
43. Landick R, Wang D, Chan CL 1996. Quantitative analysis of transcriptional pausing by Escherichia coliRNA polymerase: His leader pause site as a paradigm. Methods Enzymol 274:334-353. http://dx.doi.org/10.1016/S0076-6879(96)74029-6.
44. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-ninth edition. Approved standard M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
45. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria-ninth edition. Approved standard M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
46. Pearson RD, Steigbigel RT, Davis HT, Chapman SW 1980. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 18:699-708. http://dx.doi.org/10.1128/AAC.18.5.699.
47. Jousimies-Somer H, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Company, Belmont, CA.
48. Ferraris L, Aires J, Waligora-Dupriet AJ, Butel MJ 2010. New selective medium for selection of bifidobacteria from human feces. Anaerobe 16: 469-471. http://dx.doi.org/10.1016/j.anaerobe.2010.03.008.
49. Hartemink R, Domenech VR, Rombouts FM 1997. LAMVAB - a new selective medium for the isolation of lactobacilli from faeces. J Microbiol Methods 29:77-84. http://dx.doi.org/10.1016/S0167-7012(97)00025-0.
50. Carman RJ, Wilkins TD 1991. In vitro susceptibility of rabbit strains of Clostridium spiroforme to antimicrobial agents. Vet Microbiol 28:391-397. http://dx.doi.org/10.1016/0378-1135(91)90074-P.
51. Borriello SP, Carman RJ 1983. Association of iota-like toxin and Clostridium spiroforme with both spontaneous and antibiotic-associated diarrhea and colitis in rabbits. J Clin Microbiol 17:414-418.
52. Soukup GA, Breaker RR 1999. Relationship between internucleotide linkage geometry and the stability of RNA. RNA 5:1308-1325. http://dx.doi.org/10.1017/S1355838299990891.
53. Serganov A, Huang L, Patel DJ 2009. Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. Nature 458:233-237. http://dx.doi.org/10.1038/nature07642.
54. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449. http://dx.doi.org/10.1056/NEJMoa051639.
55. O'Connor JR, Johnson S, Gerding DN 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924. http://dx.doi.org/10.1053/j.gastro.2009.02.073.
56. Wong SS, Woo PC, Luk WK, Yuen KY 1999. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34:1-6. http://dx.doi.org/10.1016/S0732-8893(98)00139-4.
57. Babakhani F, Gomez A, Robert N, Sears P. 2011. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 60:1213-1217. http://dx.doi.org/10.1099/jmm.0.029470-0.
58. Snydman DR, Jacobus NV, McDermott LA 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448-3452. http://dx.doi.org/10.1128/AAC.06257-11.
59. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
60. Collignon A. 2010. Methods for working with the mouse model. Methods Mol Biol 646:229-237. http://dx.doi.org/10.1007/978-1-60327-365-7-15.
61. Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 35:1108-1111. http://dx.doi.org/10.1128/AAC.35.6.1108.
62. Rolfe RD, Helebian S, Finegold SM 1981. Bacterial interference between Clostridium difficile and normal fecal flora. J Infect Dis 143:470-475. http://dx.doi.org/10.1093/infdis/143.3.470.
63. Chapin KC, Murray PR 1999. Media, p 1687-1707. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
64. Savage DC, Dubos R. 1968. Alterations in the mouse cecum and its flora produced by antibacterial drugs. J Exp Med 128:97-110. http://dx.doi.org/10.1084/jem.128.1.97.
65. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB 2009. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 77: 2367-2375. http://dx.doi.org/10.1128/IAI.01520-08.
66. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility toClostridium difficile-induced colitis. Infect Immun 80:62-73. http://dx.doi.org/10.1128/IAI.05496-11.
67. Vicens Q, Mondragon E, Batey RT 2011. Molecular sensing by the aptamer domain of the FMN riboswitch: a general model for ligand binding by conformational selection. Nucleic Acids Res 39:8586-8598. http://dx.doi.org/10.1093/nar/gkr565.
68. O'Shea R, Moser HE 2008. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51:2871-2878. http://dx.doi.org/10.1021/jm700967e.
69. Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. 2006. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 50:1890-1892. http://dx.doi.org/10.1128/AAC.50.5.1890-1892.2006.
70. Langer S, Hashimoto M, Hobl B, Mathes T, Mack M. 2013. Flavoproteins are potential targets for the antibiotic roseoflavin in Escherichia coli. J Bacteriol 195:4037-4045. http://dx.doi.org/10.1128/JB.00646-13.
71. Langer S, Nakanishi S, Mathes T, Knaus T, Binter A, Macheroux P, Mase T, Miyakawa T, Tanokura M, Mack M. 2013. The flavoenzyme azobenzene reductase AzoR from Escherichia coli binds roseoflavin mononucleotide (RoFMN) with high affinity and is less active in its RoFMN form. Biochemistry 52:4288-4295. http://dx.doi.org/10.1021/bi400348d.
72. Wilson KH, Silva J, Fekety FR 1981. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun 34:626-628.
73. Britton RA, Young VB 2012. Interaction between the intestinal micro-biota and host in Clostridium difficile colonization resistance. Trends Microbiol 20:313-319. http://dx.doi.org/10.1016/j.tim.2012.04.001.
74. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
75. Seekatz AM, Young VB 2014. Clostridium difficile and the microbiota. J Clin Invest 124:4182-4189. http://dx.doi.org/10.1172/JCI72336.
76. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, Tellis PA, Brousseau R. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202:1877-1884. http://dx.doi.org/10.1086/657319.
77. Hopkins MJ, Macfarlane GT 2002. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51:448-454.
78. Rea MC, O'Sullivan O, Shanahan F, O'Toole PW, Stanton C, Ross RP, Hill C. 2012. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50:867-875. http://dx.doi.org/10.1128/JCM.05176-11.
79. Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD 2014. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. mBio 5(3):e01021-14. http://dx.doi.org/10.1128/mBio.01021-14.
80. Skraban J, Dzeroski S, Zenko B, Mongus D, Gangl S, Rupnik M. 2013. Gut microbiota patterns associated with colonization ofdifferentClostridium difficile ribotypes. PLoS One 8:e58005. http://dx.doi.org/10.1371/journal.pone.0058005.
81. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 56:2493-2503. http://dx.doi.org/10.1128/AAC.06305-11.
82. Kaatz GW, Seo SM 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 39:2650-2655. http://dx.doi.org/10.1128/AAC.39.12.2650.
83. Leive L. 1968. Studies on the permeability change produced in coliform bacteria by ethylenediaminetetraacetate. J Biol Chem 243:2373-2380.
84. Hendrickson BA, Guo J, Laughlin R, Chen Y, Alverdy JC 1999. Increased type 1 fimbrial expression among commensal Escherichia coli isolates in the murine cecum following catabolic stress. Infect Immun 67: 745-753.
85. Berg RD. 1995. Bacterial translocation from the gastrointestinal tract. Trends Microbiol 3:149-154. http://dx.doi.org/10.1016/S0966-842X(00)88906-4.
86. Gautreaux MD, Deitch EA, Berg RD 1994. Bacterial translocation from the gastrointestinal tract to various segments of the mesenteric lymph node complex. Infect Immun 62:2132-2134.
87. Douce G, Goulding D. 2010. Refinement of the hamster model of Clostridium difficile disease. Methods Mol Biol 646:215-227. http://dx.doi.org/10.1007/978-1-60327-365-7-14.
88. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect Immun 79:2856-2864. http://dx.doi.org/10.1128/IAI.01336-10.